Trial Profile
A phase I/II clinical trial of oral vorinostat (MK0683) in combination with erlotinib in patients with relapsed/refractory non-small-cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 09 Mar 2009 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 09 Mar 2009 Planned end date added to 1 Dec 2007 as reported by ClinicalTrials.gov.
- 26 Apr 2008 New trial record.